Approved for use through 7/31/2006. OMB 0651-0031
SUBSTITUTE for PTO/SB/08A (07-05), Information Disclosure Statement by Applicant
Patent and Trademark Office; U.S DEPARTMENT OF COMMERCE

					Patent and Trademark Office; U.S DEPARTMENT OF COMMERCE			
				COMPLETE IS KNOWN				
Substitute for	form 1449A/PTO	\1C/	CLIDE	Application Number	10/517,57			
	RMATION I			Filing Date	December 9, 2004			
OISTAX	EMENT BY	AP	PLICANT	First Named Inventor	Kenneth L. Arrington			
UL 2 7 2005	i)			Group Art Unit				
P (use	s many sheets	as n	ecessary)	Examiner Name				
Shoots	7 1	of 2		Attorney Docket Number	21119YP			
- Shinging -		لتلا						

		U.	S. PA	TENT DOCUMENTS	
miner	Cite	I I S. Patent Document	Kind Code known)	S.D Amplicant	Date of Publication of Cited Document MM-DD-YYYY
ials*	No.		known)	Fevig et al.	05/02/2000
/SL/		6,057,342		Sakowicz	08/27/2002
4		6,440,686		Helsey, et al.	02/22/1972
$\underline{\mathbf{V}}$	<u> </u>	3,644,414		Tiolsoy, or all	
			┼		
	-		┼		
	<u> </u>		┼		
	<u> </u>		┼		
	<u> </u>		┼	<u> </u>	·
			+		
		1.	-		
	Τ		-		
	1				
	1				
	1				
	+-		- 1		

No. Office Number Co. Co.	Examiner	Cite		Foreign Patent Docume		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	
PCT WO 98/06694 The DuPont Merck Pharm. Co. 02/19/1998 PCT WO 2005/019206 Merck & Co., Inc. 03/03/2005 PCT WO 2005/019205 Merck & Co., Inc. 03/03/2005 PCT WO 03/105855 Merck & Co., Inc. 12/24/2003 PCT WO 03/049527 Merck & Co., Inc. 06/19/2003 PCT WO 03/049527 Merck & Co., Inc. 05/06/2004 PCT WO 03/049		No.		·		Vamanouchi Pharm, Co., Ltd.	10/14/1993	
PCT WO 2005/019206 Merck & Co., Inc. 03/03/2005 PCT WO 2005/019205 Merck & Co., Inc. 03/03/2005 PCT WO 03/105855 Merck & Co., Inc. 12/24/2003 PCT WO 03/049527 Merck & Co., Inc. 06/19/2003	ISLI						02/19/1998	
PCT WO 2005/019205 Merck & Co., Inc. 03/03/2005 PCT WO 03/105855 Merck & Co., Inc. 12/24/2003 PCT WO 03/049527 Merck & Co., Inc. 06/19/2003 PCT WO 03/049527 Merck & Co., Inc. 05/06/2004		PCT W						
PCT WO 2003/019263 PCT WO 03/105855 Merck & Co., Inc. 12/24/2003 PCT WO 03/049527 Merck & Co., Inc. 06/19/2003 PCT WO 03/049527 Merck & Co., Inc. 05/06/2004								
PCT WO 03/049527 Merck & Co., Inc. 08/19/2003							12/24/2003	
105/00/2004		ļ			Merck & Co., Inc.			
	47	-				Merck & Co., Inc.	05/06/2004	
	_ V _	-	+					
		1	 					
Date 05/01/2007		1-						

05/01/2007 Date Considered Examiner Signature /Sun Jae Loewe/

				Patent and Trademark Office; U.S DEPARTMENT OF COMMISSION				
				COMPLETE LE KNOWN				
Sub	stitute for form 1449B/PTO	NO.	CUIDE	Application Number	10/517,57			
INFORMATION DISC. SURE					December 9, 2004			
STATEMENT BY APPLICANT					Kenneth L. Arrington			
				Group Art Unit				
(use as many sheets as necessary)				Examiner Name				
			2	Attorney Docket Number	21119YP			
eet 2	2	of						

Sheet		2	of	2		mey Docket Nu					
			N	ON PATE	NT LITE	RATURE D	OCUM	ENTS			
Examiner	Cite		Include	name of the au	uhor, title, d	iate, page(s), volt	ume-issu	e number(s) and p	lace of public	ation.	
Initials* /SL/	No.	C. Sonesson				ol. 61, pg. 475			<u>.</u>		
		N. Iwasawa	a, et al., J.	Org. Chem.	1998, Vo	l. 63, pg. 3164	4-3165				
		N. Iwasaw	a, et al., J.	Org. Chem.	1997, Vo	ol. 62, pg. 191	8-1919		,		
		R. Mison,	et al., J. Cl	hem. Researc	ch(S), 19	89, 126-127					
1		O. Yebdri	, et al., Bu	lletin De La	Societe C	Chimique de F	rance,	1983, pg. 195	-201	·	
- V		A Ranjor	Rulletin	De La Socie	te Chimic	que de France	1971	pg. 2068-207	2		
/SL	1	M. Bujard, et al., Tetrahedron Letters, Vol. 40, 1999, pg. 8785-8788									
IT		M. Carpes, et al., Synlett, No. 7, 2000, pg. 1037-1039 A. Boukhari, et al., J. Cryst. Spect. Res., Vol. 19, Iss. 3, 1989, pg. 603-621									
	,										
							·				
					O.						
	_										
<u> </u>											

		Date	05/01/2007]
Examiner	/Sun Jae Loewe/	Considered		
Signature	/ Cut out Edewe/	9. Draw line through citation if not	in conformance and not considered	. Include copy of